ESTRO 2023 - Abstract Book

S2035

Digital Posters

ESTRO 2023

Published scoping review methodology[8], literature identification, screening, and eligibility guidance[9] were followed. Two preliminary OVID MEDLINE® searches established common terms relating to lower GI motion and morbidity and identified predominant GI-factors. For predominant GI-factors a search strategy was created, using terms identified in preliminary searches. Searches were run on four databases: Ovid Medline®, EMBASE, CINAHL and EBSCO discovery. Articles written in English from 2010-present were included. Those pertaining to paediatrics, biological women exclusively, infectious and post-treatment GI morbidity and diet were excluded. Articles were grouped by causative factor to establish prevalent sub-factors and examine specific GI symptoms, incidence and assessment tools. The prevalence of common sub-factors in a prostate cancer population was estimated. Results The preliminary search for GI-factors (May 2021) yielded 489 articles, 87 met the inclusion/exclusion criteria. Four prominent GI-factors presented (Figure 1).

The GI-factor search (Feb. 2022) found 3644 articles; 1646 were removed as duplicates. A further 1249 were excluded after title and abstract screening, 162 remained subsequent to full text review: 42 mental health, 53 co-morbidity and medication, 39 physical activity and 28 pelvic floor disorder. Sixteen common sub-factors were identified, Figure 1 presents these and their associated GI symptoms. Prevalence of depression, anxiety, diabetes, obesity, low physical activity, and pelvic floor disorder was estimated to be considerable in a prostate cancer population. Reliable assessment tools are available and quick to complete (Figure 2).

Conclusion Sixteen GI-factors were identified. The most common six factors appear prevalent in a prostate cancer population. Reliable, quick, and easy to use tools are available to quantify these factors. We are introducing these tools to clinic practice, to establish prevalence of GI-factors in our prostate cancer population, evaluate their effect on inter- and intrafraction prostate motion and guide provision of personalised treatment and care.

PO-2263 Working with Lesbian, Gay, and Bisexual people to address their experiences in cancer care

G. Hill 1 , C. Bulley 2